Institut National De La Sante Et De La Recherche Medicale

Assistance Publique-hopitaux De Paris

Université Paris Diderot-paris 7

Université Paris 13

Pharmaleads

Inserm

François Rouzet

Jean-Baptiste Michel

Marie-Claude Fournie-Zaluski

Didier Letourneur

Hervé Poras

Frederic Chaubet

Alain Meulemans

Laure Bachelet

Dominique Leguludec

Bernard Rogues

The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.

Fucoidans as ligands for the diagnosis of degenerative pathologies

The present invention is directed to the use of an irreversible ligand of a serine protease selected from the group consisting of leukocyte elastase, thrombin, tissue plasminogen activator (t-PA) and plasmin for the molecular imaging of said serine protease and the diagnosis of pathophysiological conditions associated with said serine protease activity.

Agents for the molecular imaging of serine-protease in human pathologies

Growing community of inventors

Paris, France

François Rouzet